Mode
Text Size
Log in / Sign up

COVID-19 pandemic associated with Hashimoto's increase and Subacute Thyroiditis decrease in Israeli retrospective cohort

COVID-19 pandemic associated with Hashimoto's increase and Subacute Thyroiditis decrease in Israeli …
Photo by KOBU Agency / Unsplash
Key Takeaway
Note the association between the COVID-19 pandemic and thyroid disease incidence, acknowledging inconclusive findings.

This retrospective cohort study analyzed 4,765 incident thyroid disease cases among adults (≥16 years) in the Clalit Health Services southern district of Israel. The setting was the Clalit Health Services southern district of Israel. The follow-up period spanned January 2018 to December 2022, comparing the COVID-19 pandemic exposure against a pre-pandemic period.

Incidence patterns varied significantly across conditions. Hashimoto's Thyroiditis incidence showed a significant 30% increase with an IRR of 1.30 (95% CI 1.04-1.64, p=0.023), comprising 3,731 cases (78.3%). Subacute Thyroiditis incidence demonstrated a significant 54% reduction with an IRR of 0.46 (95% CI 0.21-0.99, p=0.049), accounting for 336 cases (7.1%). Graves' Disease incidence showed a non-significant upward trend with an IRR of 1.66 (95% CI 0.99-2.79, p=0.054), representing 698 cases (14.6%). This condition did not reach statistical significance.

Safety data were not reported, including adverse events, serious adverse events, discontinuations, or tolerability. The authors note that findings remain inconclusive and are primarily based on relatively small studies. Population-level data examining the differential impact of the pandemic on specific thyroid conditions are scarce. Consequently, practice relevance is not reported, and clinicians should recognize the association rather than causality between the COVID-19 pandemic and thyroid diseases. Further interpretation requires caution due to the observational design.

Study Details

Study typeCohort
EvidenceLevel 3
PublishedApr 2026
View Original Abstract ↓
BackgroundThe COVID-19 pandemic has been associated with various autoimmune manifestations. Several studies have suggested a potential association between COVID-19 and thyroid diseases (TDs); however, findings remain inconclusive and are primarily based on relatively small studies. Population-level data examining the differential impact of the pandemic on specific thyroid conditions are scarce.ObjectiveTo examine the incidence patterns of Hashimoto’s Thyroiditis (HT), Graves’ Disease (GD), and Subacute Thyroiditis (SAT) during the COVID-19 pandemic compared to the pre-pandemic period.MethodsWe conducted a population-based retrospective cohort study using interrupted time series analysis of adults (≥16 years) in the Clalit Health Services southern district of Israel from January 2018 to December 2022. New cases of TDs were identified using either ICD-9 codes, laboratory results, medication dispensing data or a combination of them. Monthly disease-specific incidence rates were compared between pre-pandemic (January 2018-February 2020) and pandemic (March 2020-December 2022) periods, with adjustment for seasonal variations.ResultsAmong 4,765 incident TD cases identified, 3,731 (78.3%) had HT, 698 (14.6%) had GD, and 336 (7.1%) had SAT. The mean age was similar across groups (43–45 years) with consistent female predominance (77%). Interrupted time series analysis revealed a significant 30% increase in HT incidence during the pandemic period (IRR 1.30, 95% CI 1.04-1.64, p=0.023), which began prior to the national vaccination campaign. GD showed a non-significant upward trend suggestive of a possible increased incidence (IRR 1.66, 95% CI 0.99-2.79, p=0.054). Conversely, SAT demonstrated a significant 54% reduction in incidence (IRR 0.46, 95% CI 0.21-0.99, p=0.049).ConclusionsThe COVID-19 pandemic was associated with a significant increase in HT incidence and an unexpected decrease in SAT. These findings highlight the heterogeneous impact of the pandemic on different TDs.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.